Moderna to supply 12 million doses of Omicron containing bivalent COVID booster vaccines to Govt of Canada

Published On 2022-08-22 04:00 GMT   |   Update On 2022-08-22 04:00 GMT
Advertisement

Cambridge: Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Government of Canada has exercised its option to purchase an additional 4.5 million doses of an Omicron-containing bivalent vaccine booster candidate from the Company, in addition to moving forward the scheduled delivery of 1.5 million doses of the bivalent vaccine candidate from 2023 to 2022.

Advertisement

Moderna and the Government of Canada have also agreed to convert six million doses of the Company's COVID-19 vaccine (Spikevax, mRNA-1273) to an Omicron-containing bivalent vaccine. The agreement is subject to regulatory approval of the Omicron-containing bivalent vaccine booster candidate by Health Canada, with doses scheduled for delivery in 2022.

Read also: Moderna gets Australian provisional approval for mRNA COVID-19 vaccine Spikevax in children aged 6 months to 5 years

"We thank the Government of Canada for their trust in our mRNA technology and our next-generation bivalent COVID-19 vaccine platform," said Stéphane Bancel, Moderna's Chief Executive Officer. "As we have seen throughout this pandemic, the Government of Canada continues to take important steps in preparing for the winter season and protecting its people against Omicron."

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News